In a subgroup analysis, 99% of patient days
were attack free for up to 2.7 years2†
HAEGARDA is the only HAE preventive therapy that delivers:
The WAO Guideline for the Management of HAE states that patients should have HAE rescue
medication available at all times.4
References:
1. Craig T, Feuersenger H, Pragst I. Durability of symptom control with long-term prophylactic therapy with subcutaneous C1-inhibitor in patients with hereditary angioedema. Presented at: 33rd Annual Eastern Allergy Conference;August 16-18, 2020; Palm Beach, FL.
2. Craig T, Feuersenger H, Pragst I, et al. Prophylactic therapy with subcutaneous C1-inhibitoris associated with sustained symptom control in patients with hereditary angioedema. Allergy Asthma Proc. 2022;43:202-208.
3. Longhurst H, Cicardi M, Craig T. COMPACT Investigators. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017;376(12):1131-1140.
4. Maurer M, Magerl M, Betschel S, et al. The international WAO/EACCI guideline for the management of hereditary angioedema — the 2021 revision and update. WAO Journal. 2022;15:1-39.
Have additional questions?
Connect with CSL Behring Medical Affairs to find
additional information and ask questions.